接受新辅助化疗的癌症患者静脉血栓栓塞症:系统评价与荟萃分析
该系统评价纳入28项队列研究共7827例接受新辅助治疗的癌症患者,其中25项为回顾性设计。7768例中508例发生至少一次静脉血栓栓塞症(VTE),汇总发生率为7%(95%CI 5%至10%),研究间异质性不显著。膀胱癌(10.6%)和食管癌(8.4%)患者VTE发生率最高。
要点
- 接受新辅助治疗的癌症患者VTE汇总发生率为7%(95%CI 5%至10%)。
- 膀胱癌(10.6%)和食管癌(8.4%)患者VTE发生率最高。
- VTE在部分队列中以肺栓塞(22%至96%)或症状性(22%至100%)形式出现。
核心结论
- 本综述发现接受新辅助治疗的癌症患者VTE发生率相对较高,且存在一定研究间变异,值得在前瞻性研究中进一步评估。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE和EMBASE数据库(自建库至2017年10月),并补充筛查美国临床肿瘤学会(2009-2016)和国际血栓与止血学会(2003-2016)会议论文集。
- 纳入28项队列研究,共7827例癌症患者(范围11至1398例),其中25项为回顾性设计。
- 18个队列纳入胃肠道癌症患者,占整个研究人群的三分之二以上(n=6002,78%)。
主要发现
- 7768例患者中508例在新辅助治疗期间诊断至少一次VTE,汇总VTE发生率为7%(95%CI 5%至10%),研究间异质性不显著。
- 异质性未能由癌症部位或研究设计特征解释。
- VTE表现为肺栓塞者占22%至96%(16个队列),表现为症状性者占22%至100%(11个队列)。
- 膀胱癌患者VTE发生率最高(10.6%),其次为食管癌(8.4%)。
关键数值与推荐
- 汇总VTE发生率为7%(95%CI 5%至10%)。
- 膀胱癌患者VTE发生率为10.6%,食管癌患者为8.4%。
- 肺栓塞占VTE病例的22%至96%(16个队列),症状性VTE占22%至100%(11个队列)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 25项研究为回顾性设计。
- 存在一定研究间变异,值得在前瞻性研究中进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Cancer patients are at risk for venous thromboembolism (VTE). The risk of VTE in less advanced stage cancer on neoadjuvant chemotherapy is unclear. In over 7800 patients, we found a 7% pooled incidence of VTE during neoadjuvant therapy. Highest VTE rates were observed in patients with bladder and esophageal cancer. SUMMARY: Background Venous thromboembolism (VTE) is a frequent complication in cancer patients receiving adjuvant treatment. The risk of VTE during neoadjuvant chemo-radiotherapy remains unclear. Objectives This systematic review evaluated the incidence of VTE in patients with cancer receiving neoadjuvant treatment. Methods MEDLINE and EMBASE databases were searched from inception to October 2017. Search results were supplemented with screening of conference proceedings of the American Society of Clinical Oncology (2009-2016) and the International Society of Thrombosis and Haemostasis (2003-2016). Two review authors independently screened titles and abstracts, and extracted data onto standardized forms. Results Twenty-eight cohort studies (7827 cancer patients, range 11 to 1398) were included. Twenty-five had a retrospective design. Eighteen cohorts included patients with gastrointestinal cancer, representing over two-thirds of the whole study population (n = 6002, 78%). In total, 508 of 7768 patients were diagnosed with at least one VTE during neoadjuvant treatment, for a pooled VTE incidence of 7% (95% CI, 5% to 10%) in the absence of substantial between-study heterogeneity. Heterogeneity was not explained by site of cancer or study design characteristics. VTE presented as pulmonary embolism in 22% to 96% of cases (16 cohorts), and it was symptomatic in 22% to 100% of patients (11 cohorts). The highest VTE rates were observed in patients with bladder (10.6%) or esophageal (8.4%) cancer. Conclusions This review found a relatively high incidence of VTE in cancer patients receiving neoadjuvant therapy in the presence of some between-study variation, which deserves further evaluation in prospective studies.
引用
- Di Nisio M, Candeloro M, Rutjes AWS, et al. Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. J Thromb Haemost. 2018. PMID: 29754426. doi:10.1111/jth.14149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。